Business Wire

CA-VISA-INC.

16.11.2023 14:01:33 CET | Business Wire | Press release

Share
New Visa Report Tells Consumers to Stay Alert this Holiday Shopping Season

Today, Visa Inc., a world leader in digital payments, revealed its Holiday Edition Threats Report, which anticipates heightened scam activity during the holiday season across both card-present (CP) and card-not-present (CNP) transactions. The new report identifies popular fraud tactics expected between November 2023 and January 2024 due to the rapid increase in eCommerce activities and in-person spending across retail and hospitality. Visa, today, also unveiled its list of top 10 habits consumers can follow to practice safe and secure shopping.

Historical data and transactions show that threat actors prey on consumers during the holiday season. In fact, Visa’s data shows that for the top merchant categories targeted by fraudsters, 2022 holiday fraud rates increased 11% over their non-holiday fraud rate and saw an increase of 8% over the previous year during this time1. The Holiday Edition Threats Report warns that threat actors will seek to exploit consumers’ increased interest and urgency in finding deals and one-of-a-kind gifts. Highlights of the report’s findings include:

  • Digital Skimming: With the increase in online shopping, there’s a greater opportunity for scammers to successfully compromise account data from eCommerce merchants and monetize it.
  • Phishing and Social Engineering: The advancement of artificial intelligence (AI) over the past year provides threat actors with the ability to create highly customized phishing campaigns, making it harder for consumers to spot fakes. Fraudsters also create phishing websites, often using malvertising (malicious advertising) and other illicit search engine optimization (SEO) tactics on retail or service websites to entice victims.
  • ATM / POS Skimming: With the increase in foot traffic at brick-and-mortar merchants and ATMs, threat actors will likely target ATM and POS terminals with skimming attacks.
  • OTP Bypass and Provisioning Fraud: Visa identified many one-time-passcode (OTP) bypass schemes to gain access to cardholders’ accounts. In this scheme, OTP templates are sent to the victims that appear to be associated with desired purchase.
  • Physical Theft: Threat actors may attempt to physically steal payment cards and/or phones from unsuspecting consumers in crowded retail stores, shopping malls, or parking lots.

“Crooks prepare all year for the holiday shopping season, taking advantage of increased activity and consumers who let their guard down searching for the perfect gift,” said Paul Fabara, Chief Risk Officer, Visa. “At Visa, we are committed to security and reliability, with a promise of 24/7 threat monitoring, even during the busiest time of the year. Consumers can rest easy this holiday season knowing Visa’s team of experts is working around the clock to stop fraud in its tracks.”

10 Habits to Help Consumers Shop Securely

Visa’s 10 Habits for Good Security Hygiene can guide consumers who are planning to shop this holiday season on best practices to stay safe. Highlights from Visa’s tips include:

  • Double Check Reputation and Authenticity of Retailers: Stick to trusted and retailers you know well. If you're considering a purchase from a store you're not familiar with, do some research to check their reputation and authenticity.
  • Secure Your Personal Information: Make sure the website uses secure technology. When at the checkout, the website address should start with 'https://'. The 's' stands for secure and means that your data is being encrypted and sent over a secure connection.
  • Avoid Public Wi-Fi for Shopping: Public Wi-Fi networks are often unsecured, which makes it easier for hackers to steal your information. Always use a secure, private internet connection when you're making purchases.
  • Beware of Deals That Are Too Good to Be True: Offers on websites and in unsolicited emails can often sound too good to be true, especially extremely low prices on hard-to-get items. Consumers should be suspicious of such deals, as they often are.

At Visa, security and reliability is a top priority year-round. Over the past five years, the company has invested more than $10 billion in technology, including to reduce fraud and increase network security. More than a thousand dedicated specialists protect Visa’s network from malware, zero-day attacks and insider threats 24x7x365. In fact, in the first six months of 2023, Visa helped to proactively block $30 billion in fraud, preventing many from ever knowing they were at risk of a potential fraudulent transaction. We encourage consumers to stay alert during this season and think about where they are shopping and who they are sharing their information with to keep it safe.

About Visa Inc.

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

1 Top merchant categories include home improvement and supply, telecommunications, business to business, healthcare, automotive, entertainment, education and government, lodging, insurance, airlines, and drug store and pharmacies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116325184/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye